FoxG1 antagonizes neocortical stem cell progression to astrogenesis by Falcone, Carmen et al.
09 March 2020
.                                       SCUOLA INTERNAZIONALE SUPERIORE DI STUDI AVANZATI
                                                                               SISSA Digital Library
FoxG1 antagonizes neocortical stem cell progression to astrogenesis / Falcone, Carmen; Santo, Manuela; Liuzzi,
Gabriele; Cannizzaro, Noemi; Grudina, Clara; Valencic, Erica; Peruzzotti-Jametti, Luca; Pluchino, Stefano; Mallamaci,
Antonio. - In: CEREBRAL CORTEX. - ISSN 1047-3211. - 29:12(2019), pp. 4903-4918.
Original
FoxG1 antagonizes neocortical stem cell progression to astrogenesis
Oxford University Press
Publisher:
Published
DOI:10.1093/cercor/bhz031
Terms of use:
openAccess
Publisher copyright
This version is available for education and non-commercial purposes.
(Article begins on next page)
Testo definito dall’ateneo relativo alle clausole di concessione d’uso
Availability:
This version is available at: 20.500.11767/87874 since: 2019-03-10T16:57:50Z
This is the peer reviewd version of the followng article:
 Title 
Foxg1 antagonizes neocortical stem cell progression to astrogenesis 
 
 
 
Authors 
Carmen Falcone (1,2), Manuela Santo (1), Gabriele Liuzzi (1), Noemi Cannizzaro (1), Clara Grudina (1,,3), Erica 
Valencic (4), Luca Peruzzotti-Jametti (5), Stefano Pluchino (5), Antonello Mallamaci (1,*) 
 
 
 
Affiliations 
(1) Laboratory of Cerebral Cortex Development, Neuroscience Area, SISSA, Trieste, Italy 
(2) present address: Institute for Pediatric Regenerative Medicine and Shriners Hospitals for Children Northern 
California, UC Davis, Sacramento, CA, USA 
(3) present address: Istitut Pasteur, Paris, France 
(4) Department of Diagnostics, Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy 
(5) Department of Clinical Neurosciences - Division of Stem Cell Neurobiology, Wellcome Trust-Medical 
Research Council Stem Cell Institute and NIHR Biomedical Research Centre, University of Cambridge, UK 
(*) corresponding author [address: via Bonomea 265 - 34136 Trieste - Italy; phone: +39 040 3787 717; e-mail: 
amallama@sissa.it] 
	
 
 
Running title 
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ABSTRACT 
Neocortical astrogenesis follows neuronogenesis and precedes oligogenesis. Among key factors dictating its 
temporal articulation, there are progression rates of pallial stem cells (SCs) towards astroglial lineages as well as 
activation rates of astrocyte differentiation programs in response to extrinsic gliogenic cues. In this study, we 
showed that high Foxg1 SC expression antagonizes astrocyte generation, while stimulating SC self-renewal and 
committing SCs to neuronogenesis. We found that mechanisms underlying this activity are mainly cell 
autonomous and highly pleiotropic. They include a concerted downregulation of four key effectors channelling 
neural SCs to astroglial fates, as well as defective activation of core molecular machineries implementing 
astroglial differentiation programs. Next, we found that SC Foxg1 levels specifically decline during the 
neuronogenic-to-gliogenic transition, pointing to a pivotal Foxg1 role in temporal modulation of astrogenesis. 
Finally, we showed that Foxg1 inhibits astrogenesis from human neocortical precursors, suggesting that this is 
an evolutionarily ancient trait.  
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  Neocortical astrocytes are generated according to a peculiar, spatio-temporal and clonal pattern. They 
originate from neural precursors located in neopallial periventricular layers (Gorski et al. 2002; Tsai et al. 2012), 
largely via committed progenitors. Still intermitotic, these progenitors migrate towards more marginal layers, 
where they locally proliferate and give rise to mature differentiated progenies (Ge et al. 2012; Magavi et al. 
2012) Astrogenesis initiates at low levels at mid-neuronogenic stages and peaks up after neuronogenesis 
completion (Okano and Temple 2009). Clonal trees originating from isolated, early pallial stem cells reveal the 
early occurrence of neuronal progenitors and later appearance of glia- and astroglia-committed precursors (Qian 
et al. 2000). All these precursors are detectable in vivo along a largely consistent temporal progression (Costa et 
al. 2009).	
 Among processes dictating the ultimate neocortical astroglial output there is the transition from early 
neural stem cells (NSCs) to astrocyte-committed progenitors, namely a key developmental step requiring an 
accurate molecular control. This control is exerted by a large set of genes, most of which have been implicated in 
a dense and intricate functional network (Mallamaci 2013; Kanski et al. 2014; Sloan and Barres 2014; Takouda 
et al. 2017). A small group of transcription factors, including CouptfI/II, Zbtb20, Sox9 and Nfia, promote the 
astrogenesis onset, partly by changing the epigenetic state of astroglial genes (Naka et al. 2008; Namihira et al. 
2009; Kang et al. 2012; Nagao et al. 2016). Once chromatin of genes active in astroglia gets permissive, then its 
transcription rate results from the interaction among dedicated signalling pathways, impinging on astroglial 
promoters. Some of them inhibit astroglial gene transcription (e.g. Nrg1/ErbB4ICD-NCoR (Hermanson et al. 
2002; Sardi et al. 2006; Schlessinger and Lemmon 2006; Miller and Gauthier 2007)), some others promote it 
(e.g. IL6/Jak2/Stat1,3 (Derouet et al. 2004; Barnabé-Heider	 et	 al.	 2005;	 He	 et	 al.	 2005),  Bmp/Smad1,5,8 
(Nakashima 1999; Sun et al. 2001), Dll1/Notch1ICD (Ge et al. 2002; Kamakura et al. 2004).	
 We previously found that pallial NSC-restricted overexpression of Foxg1, an ancient transcription factor 
controlling telencephalic specification (Hanashima et al. 2007), subpallial/pallial fate (Manuel et al. 2010; 
Mariani et al. 2015; Patriarchi et al. 2016), hippocampal programs (Muzio and Mallamaci 2005)and 
neuronogenesis progression (Chiola et al. in press; Miyoshi and Fishell 2012; Toma et al. 2014), leads to a 
substantial decrease of astrocyte generation (Brancaccio et al. 2010). However, we demonstrated the occurrence 
of this phenomenon only in a murine, heterochronic in vitro system, we did not address its physiological 
relevance and, last, we did not focus on molecular mechanisms underlying it (Brancaccio et al. 2010).	
 In this study we showed that Foxg1 overexpression within neocortical stem cells commits these cells to 
neuronogenesis rather than astrogenesis, in vivo as well as in vitro, both in mouse and human. Interestingly, we 
found that Foxg1 inhibition of astrogenesis stems from variegated mechanisms. These include a direct trans-
repression of genes biasing neural stem cells to astroglial fates, as well as an articulated impact on key pathways 
which modulate astroglial gene transcription, resulting into a robust dampening of it. Finally, we provided 
evidence that Foxg1 levels decline, while neocortical NSCs move from neuronogenesis to gliogenesis. 
These findings point to an evolutionarily conserved, pivotal role of Foxg1 in fine temporal regulation of 
astrogenesis. They also suggest that neurological symptoms observed in syndromes with altered Foxg1 allele 
dosage (Guerrini and Parrini 2012) might be partially caused by an unbalanced astrocyte generation.	
 
 
MATERIALS AND METHODS	
 
Animal Handling and Embryo Dissection 
 Animal handling and subsequent procedures were in accordance with European and Italian laws 
[European Parliament and Council Directive of September 22, 2010 (2010/63/EU); Italian Government Decree 
of March 04, 2014, n° 26]. Experimental protocols were approved by SISSA OpBA (Institutional SISSA 
Committee for Animal Care) and authorized by the Italian Ministery of Health (Auth. N° 1231/2015-PR of Nov 
25, 2015). 
 Wild type (strain CD1, purchased from Envigo, Italy) and Foxg1+/- strain (Hébert	and	McConnell	2000) 
were maintained at the SISSA animal facility. Embryos were staged by timed breeding and vaginal plug 
inspection. Pregnant females were sacrificed by cervical dislocation. Embryonic cortices were dissected out in 
cold 1X-phosphate buffered saline (PBS), under sterile conditions.	
 
Derivation of human neocortical precursor line 
 NPCs were derived from the cerebral cortex of a single 10.2 post conception week (PCW) human foetus, 
collected from routine termination of pregnancies under full ethical approval in line with Department of Health 
guidelines (LREC 96/085;96/085 - In vitro study of post-mortem human foetal neural tissue, blood and 
haematopoietic organs, approved by Cambridge Central Ethics Committee). Cells were grown and expanded in a 
chemically defined, serum-free medium in the presence of Fibroblast Growth Factor 2 (Fgf2) and Epidermal 
Growth Factor (Egf) (10 and 20 ng/ml, respectively) and routinely assessed for multipotency, as described 
(Pluchino et al. 2009).	
 
Derivation of human neocortical precursor line, Lentiviral Vectors Packaging and Titration, Engineering 
cells for in vivo transplantation, In vivo neural precursor cell transplantation, Histology brain sample 
preparation, Cortical cultures, for differentiation assays, and mRNA profiling, Immunofluorescence 
analysis, Analytical cytofluorimetry: cell preparation and analysis, Preparative cytofluorimetry: cell 
preparation and sorting, RNA profiling: qRT-PCR, ChIP-qPCR. 	
 They were performed according to standard protocols. Temporal articulation of protocols and molecular 
tools for their implementation are illustrated in dedicated figure panels (see Fig. 1-6 and S8). Full protocol 
details, including lists of lentiviruses,  PCR oligo sequences and antibodies employed, are provided in 
Supplementary Materials 
 
RESULTS 
 
Foxg1 overexpression in murine neocortical neural stem cells antagonizes astrogenesis. 
 Previous investigations in our lab gave evidence for a reduction of the astroglial output following Foxg1 
overexpression in NSCs (Brancaccio et al. 2010). However, this phenomenon was only documented in vitro, as 
well as in a temporal frame delayed as compared to the standard astrogliogenic schedule (Okano and Temple 
2009) Based on these findings, we hypothesized that Foxg1 might also control the physiological, timed 
progression of neocortical neural stem cells towards glial fates. To test this hypothesis, we decided to assess if 
Foxg1 overexpression impacts the in vivo astroglial output of genetically manipulated NSCs transplanted into 
wild type recipient brains, according to a developmentally plausible schedule. For this purpose, we engineered 
dissociated E12.5 cortico-cerebral precursors for conditional, TetON-driven Foxg1 overexpression, under the 
control of a Nestin gene-derivative promoter (pNes) selectively firing in NSCs (Brancaccio et al. 2010). We 
acutely activated the transgene via doxycyclin administration and we maintained cells in a pro-proliferative 
medium for seven days. Then, we transplanted cells into the parietal cortico-cerebral parenchyma of P0 
isochronic mouse pups. Specifically, we injected a 1:1 mix of cells, made alternatively gain-of-function (GOF) 
for Foxg1 or a control, and labelled with EGFP and mCherry, respectively. Four days later, we sacrificed the 
pups and scored their brains for the astroglial outputs of the two different, transplanted precursor types (Fig. 1 
A,D). For this purpose, we took advantage of S100b, a Ca2+-binding protein shared by ependyma and glial 
lineages, mainly expressed by astroglial cells of perinatal neocortical tissue (Deloulme et al. 2004; Raponi et al. 
2007; Falcone et al. 2015). We found that, compared to controls,  S100β+ derivatives of Foxg1-GOF cells were 
reduced by 19.25±6.94% (p<9.60x10-6, n=8,8, paired t-test) (Fig. 1E, right, and S1B). As Foxg1 also promotes 
NSCs self-renewal (Brancaccio et al., 2010), we reasoned that this might lead us to underestimate the actual 
impact of Foxg1 overexpression on the NSC astrogenic bias. Therefore, to compensate for such an effect, first, 
we evaluated the frequency of Nestin+ NSCs within sister cell preparations, engineered like the transplanted ones 
(but not labelled by EGFP or mCherry) and kept in pro-proliferative medium for 7 days (Fig. 1 A,D).  Then, we 
normalized the in vivo astroglial output of transplanted cells against such frequency. We found that Foxg1 
overexpression induced a 2.5-folds increase of Nestin+ cells (+149.76±6.34%, p<4.55x10-7, n=3,3) (Fig. 1E, 
left, and S1A), meaning that the average, NSCs-normalized S100β+ astrocytic output was decreased by as much 
as 67.67%.	
 To corroborate these results, we performed a specular loss-of-function assay, employing neural 
precursors alternatively engineered by an αFoxg1-shRNA-expressing-LV or a control (Fig. 1B,D). Here we 
expected an enlargement of the astroglial output. Consequently, to increase the sensitivity of the assay, we 
interrogated E12.5 precursor derivatives kept in vitro for only 4 days being therefore further from the astrogenic 
peak. Specifically, we co-transplanted these cells as 1:1 mixes into heterochronic P0 pups and we assessed their 
final glial output at P4. The S100β+ cells frequency did not change upon Foxg1 manipulation (n=4,4) (Fig. 1F, 
right, and S1D). However, on the day of transplantation, the frequency of Nestin+ cells was decreased by 
32.14±3.26% (p<1.12x10-3, n=3,3) in αFoxg1-shRNA samples compared to controls (Fig. 1F, left, and S1C). 
This means that αFoxg1-shRNA manipulation upregulated the average, NSC-normalized astrogenic output by 
39.75%. 
 To further validate these results, we repeated our gain-of-function assay restricting the manipulation of 
Foxg1 NSC levels to the in vivo environment. To this aim, we kept dissociated E11.5 cortico-cerebral precursors, 
made acutely Foxg1-GOF under pNes/TetON control, for three days in a doxy-free pro-proliferative medium. 
Then, we transplanted a 1:1 mix of these cells (EGFP-labelled) and their controls (mCherry-labelled) into the 
lateral ventricle of E14.5 isochronic mouse embryos. Last, we activated Foxg1 and control transgenes via oral 
doxycyclin administration to pregnant females. We allowed the embryos to be born, we sacrificed the pups at P4, 
and we evaluated the astroglial outputs of the two different, transplanted precursor types (Fig. 1C,D). Similarly 
to the first Foxg1-GOF assay, we found that S100β+ derivatives of Foxg1-GOF precursors were robustly reduced 
compared to controls (-24.08±11.03%, p< 0.01, n=4,4, paired t-test) (Fig. 1G and S1E), so definitively pointing 
to a genuine Foxg1 anti-astrogenic activity. 
 To model molecular mechanisms underlying this activity, we considered to investigate them in 
dissociated neural cultures. To confirm the feasibility of this approach, we first verified if the outcome of Foxg1 
manipulation could be fully replicated in these cultures, within a biologically acceptable temporal framework. 
For this purpose, we engineered dissociated E12.5 cortico-cerebral precursors for conditional Foxg1 
overexpression as described above for transplantation assays, we maintained these cells in a pro-proliferative 
medium for seven days, and we allowed them to differentiate on poly-L-lysin-coated coverslips for four 
additional days. We kept the Foxg1 transgene on during the entire procedure. Following Foxg1 overactivation, 
we found a pronounced loss of S100β+ astrocytes (-63.89±9.14%, p<0.003, n=4,4) as well as a consistent 
reduction of Gfap+ cells (-37.32±20.10%, p<0.002, n=3,3) (Fig. 1H,I and S1G,H) [Gfap is an intermediate 
filament protein, mainly confined to astrocytes of rodent neocortex (Malatesta et al. 2008)]. Remarkably, this 
anti-differentiative effect was specific to the astroglial lineage, as, within the same cultures, the frequency of 
Tubb3+ neurons was almost doubled (+90.45±4.53%, p<0.03, n=3,3) (Fig. 1H,I and S1I). In a second test, 
astroglial cultures were conversely prepared from Foxg1+/- (Hébert	and	McConnell	2000) mice-derived cortico-
cerebral precursors. In this case, no S100β+ output change was detected compared to wild type controls (Fig. 
1J,K and S1K). As in previous in vivo assays, we also evaluated the frequencies of NSCs in both Foxg1-GOF 
and -LOF cultures and used them to normalize the number of S100β+ and Gfap+ cells. [Here, NSCs were 
identified as expressing Sox2 but not an mCherry reporter under the control of the neuronogenic-lineage-specific 
Tubulin-α1 promoter (Fig. 1H,J)]. Interestingly, we found that, at day in vitro (DIV) 4, NSCs were augmented 
by 89.64±10.67% (p<0.0001, n=4,4) in Foxg1-GOF cultures and decreased by 26.95% in Foxg1-LOF cultures 
(Fig. 1I,K and S1F,J). This implicates that the average, NSC-normalized astrocytic output varied by -80.96% 
(S100β+ cells) and -52.41% (Gfap+ cells) in Foxg1-GOF cultures, as well as by +32.93%  (S100β+ cells) in 
Foxg1-LOF cultures.	
 It is possible that what we observed in our assays did not depend on NSC fate choice, but it alternatively 
reflected an altered kinetic behaviour of astrocyte-committed progenitors originating from engineered NSCs. To 
fix this issue, we repeated the in vitro Foxg1-GOF assay adopting three ad hoc devices. First, we  ran it over a 
shorter temporal window (four days for proliferation and two days for differentiation). Second, we took 
advantage of LIF stimulation to unmask early astroglial committed precursors. Third, we engineered both 
Foxg1-GOF and control preparations by lentiviruses harboring an additional IRES-EGFP module under 
pNes/TetON control, labelling NSCs and their immediate progenies, and we evaluated the Gfap+EGFP+/EGFP+ 
ratio of each experimental preparation, as a more direct index of NSC-to-astroblast transition. Interestingly, we 
found that this ratio was diminished by 52.51±3.61% in Foxg1-GOF samples compared to controls (p<4.7*10-5, 
n=4,4) (Fig. 1L,M and S1L), so confirming the negative impact exerted by Foxg1 on the NSC astrogenic bias. 
 To secure this interpretation, we scored Foxg1-mutant NSCs by a classical clonal assay. Specifically, we 
made E11.5 cortico-cerebral precursors Foxg1-GOF or -LOF by dedicated lentiviral effectors, we kept them as 
floating neurospheres for four days, we let them attach on poly-D-lysinated coverslips at clonal density, and we 
evaluated their clonal outputs three days later (Fig. 1N). We observed a decrease of neuron-astrocyte-mixed 
clones in Foxg1-GOF assays (5.27±0.94% in mutants vs 25.45±1.24% in controls,  p<10-5 n=4,4) and an 
increase of these clones in -LOF assays (32.83±2.33% in mutants vs 24.81±3.19% in controls,  p<0.04, n=4,4). 
In case of Foxg1-GOF assays, we also found a decrease of astrocyte-only clones (1.38±0.48% in mutants vs 
5.07±0.75% in controls,  p<3.1*10-3, n=4,4) as well as a concomitant increase of neuron-only clones 
(72.55±1.33% in mutants vs 60.56±2.14% in controls,  p<1.6*10-3, n=4,4)  (Fig. 1O,P and S1M,N). Altogether, 
these data show that, in addition to stimulating NSC self-renewal, Foxg1 antagonizes the NSC shift from 
neuronogenic towards astrogenic fates. 	 Finally,	before investigating specific antiastrogenic mechanisms driven by Foxg1, we wondered about 
their general articulation, cell-autonomous or not cell-autonomous. As Foxg1-GOF precursors gave rise to 
reduced astroglial outputs upon their transplantion into wild type brains (Fig. 1A,E), we expected that cell-
autonomous mechanisms should play a likely prevalent role in this context. To corroborate this inference and 
unveil possible, collateral non-autonomous processes, we repeated the test shown in Fig. H1,I, with some ad hoc 
modifications. Specifically, we monitored the histogenetic behaviour of aliquots of sensor (S) E12.5 wild type 
pallial precursors, acutely labelled by a constitutively expressed mCherry transgene, following their 1:4 co-
culture with isochronous conditioner (C) precursors, pre-made gain-of-function for Foxg1 or a control (Fig. 1Q). 
It turned out that the ratio among Gfap+mCherry+ astrocytes and total mCherry+ cells was not affected by the 
"genotype" of the co-cultured C-derivative population, while Foxg1 overexpression by C-founders down-
regulated the fraction of their descendants expressing Gfap (-19.44±2.69%, p<2.3*10-3, n=6,5) (Fig. 1R). All 
that confirms that Foxg1 inhibition of astrogenesis largely relies on cell-autonomous mechanisms and suggests 
that non-cell-autonomous processes hardly contribute to it.	
	
Foxg1 antagonizes the NSC astrogenic progression by downregulating key transcription factors 
channelling NSCs to astrogenic fates. 
 We hypotesized that the anti-astrogenic activity of Foxg1 could primarily originate from its ability to 
down-regulate a small set of key transcription factor genes promoting the neuronogenic-vs-astrogenic switch: 
Couptf1, Sox9, Nfia and Zbtb20 (Naka et al. 2008; Kang et al. 2012; Nagao et al. 2016). In fact, Foxg1 is a well 
known transcriptional inhibitor (Li et al. 1995; Yao et al. 2001). Moreover,  as resulting from Jaspar analysis 
(Mathelier et al. 2014), Couptf1, Sox9, Nfia and Zbtb20 loci harbor a number of putative Foxg1-binding sites, 
among which a few high-score, evolutionarily conserved ones (Fig. S2A-D). We tested this prediction in pre-
gliogenic neocortical precursors made Foxg1-GOF by somatic lentiviral transgenesis (Fig. 2A-C; control-norm-
[Foxg1-mRNA] = 4.42±0.64, not shown). As expected, all four genes resulted to be down-regulated upon Foxg1 
overexpression, by -41.5±7.01% (p<0.045, n=4,4), -30.98±5.05% (p<0.046, n=6,6), -55.85±4.73% (p<0.003, 
n=6,6), and -24.30±9.34% (p<0.038, n=6,6), respectively (Fig. 2D,E). No changes were conversely detectable 
in Foxg1-knockdown cultures (Fig. 2B,C,F; control-norm-[Foxg1-mRNA] = 0.65±0.04, not shown), suggesting 
that gene down-regulation observed in Foxg1-GOF preparations did not reflect a dominant-negative effect.	
 Then, to assess functional relevance of these phenomena to Foxg1 anti-astrogenic activity, as a proof-of-
principle, we overexpressed Zbtb20 and Nfia in wild type (Fig. S3A-C) and Foxg1-overexpressing precursors 
and we evaluated the histogenetic outcome of these manipulations by dedicated clonal assays (Fig. 2G). While 
not fully rescuing the Foxg1-GOF phenotype, the transduction of a constitutively active Zbtb20 transgene into 
Foxg1-GOF cultures mitigated the absolute frequency decrease of neuronal-astroglial and astroglial clones 
evoked by Foxg1 overexpression compared to controls (from -25.37% to -13.11%,  p<0.009, n=4,4, and from -
7.51% to -4.55%, (p<0.021, n=4,4, respectively). [Here, control frequencies of neuronal-astroglial and astroglial 
clones were 36.23±2.14% and 8.89±1.70%, respectively]. On the other side, Zbtb20 alone did not significantly 
alter the frequencies of the different clone types. This suggests that, rather than simply compensating for it, 
Zbtb20 transduction partially rescued a key molecular event mediating Foxg1 impact on NSC fate choice (Fig. 
2H and S4A). As for Nfia, its overexpression in Foxg1-GOF NSCs fully restored the drop of mixed clones 
caused by Foxg1 upregulation [these clones were as little as 5.63±0.48% in Foxg1-GOF cultures compared to 
21.69±3.53% in controls (p<0.002, n=4,4)], while not affecting the prevalence of these clones if elicited in 
control NSCs. Moreover, Nfia also abolished the slight increase of neuronal clones (75.17±1.73% vs 
69.49±2.43%, p<0.049, n=4,4) as well as the decrease of astroglial ones (1.24±0.46% vs 4.62±0.79%, p<0.005, 
n=4,4) caused by Foxg1 overexpression. Remarkably, however, its overactivation in control NSCs almost halved 
the frequency of neuronal clones (40.19±2.03% vs 69.49±2.43%, p<0.001, n=4,4) and elicited a massive 
increase of astroglial ones (24.99±1.17% vs 4.62±0.79%, p<0.001, n=4,4) (Fig. 2I and S4B). All this indicates 
that, in addition to rescuing the Foxg1-GOF phenotype, the Nfia transgene also overcompensated for it. 
 Finally, to cast light on molecular mechanisms mediating Foxg1-driven downregulation of Couptf1, 
Sox9, Nfia and Zbtb20, we profiled chromatin of mid-neuronogenic neocortical precursors, both control and 
Foxg1-GOF, for Foxg1 recruitment at selected regions of the corresponding loci, by Chromatin Immuno-
Precipitation (ChIP)-qPCR.  (Fig. 2J). Specifically, nine Foxg1-BSs were inspected, 2 for Couptf1, 3 for Zbtb20, 
2 for Sox9 and 2 for Nfia. These BSs included four putative ones selected by Jaspar software (Mathelier et al. 
2014), with score index above 14 ([J14]Foxg1-BSs), and shared by mice and humans, as well five experimentally 
verified ones, reported by the NCBI-GEO database ([EXP]Foxg1-BSs) (Fig. S2A-D). In general, all these BSs 
were specifically enriched in aFoxg1-immuno-precipitates compared to IgG-treated samples (however this does 
not apply to Couptf1-Foxg1-BS.h1 and Nfia1-Foxg1-BS.h1 in control aFoxg1-immuno-precipitates) (Fig. 2K). 
Interestingly, in case of Couptf1, Sox9 and Nfia loci, there was at least one BS significantly over-enriched in 
Foxg1-GOF compared to control aFoxg1-immuno-precipitates [BSs displaying Foxg1-responsive enrichment 
included: Couptf1-Foxg1-BS.h1 (3.83±0.43% vs 1.60±0.24%, p<0.005, n=4,3), Couptf1-Foxg1-BS.a 
(1.36±0.15% vs 0.88±0.19%, p<0.050, n=4,4), Sox9-Foxg1-BS.h1 (2.02±0.25% vs 1.25±0.26%, p<0.025, n=4,3) 
and Nf1a-Foxg1-BS.h1 (4.56±0.47% vs 2.66±0.41%, p<0.017, n=4,3)] (Fig. 2K). All this suggests that Foxg1 
directly trans-represses Couptf1, Sox9, Nfia and Zbtb20, and that such trans-repression may contribute to the 
decline of Couptf1, Sox9 and Nfia transcripts occurring in Foxg1-GOF precursors.	
 
Foxg1 antagonizes astrogenesis by directly transrepressing astroglial genes. 
 We hypothesized that Foxg1 inhibition of astrogenesis could be further strenghtened by a direct impact 
of Foxg1 on genes implementing the astroglial differentiation program. To assess this issue, first we investigated 
the response of selected astroglial genes, Gfap, S100b and Aqp4, to Foxg1 manipulation. For this purpose, we 
employed E14.5 cortico-cerebral precursors engineered for TetON-controlled Foxg1 overexpression, kept in the 
presence of growth factors and terminally pulsed by LIF (Fig. 3A). As expected, we found that Gfap-, S100b- 
and Aqp4-mRNA levels were significantly decreased, by -49.92±13.25% (p<0.03, n=6,6),  -46.79±16.91% 
(p<0.03, n=5,5), and -43.98±14.70% (p<0.03, n=5,5), respectively (Fig. 3B, left). No statistically significant 
changes of these mRNAs were observed in a specular Foxg1-LOF assay (Fig. 3B, right), so ruling out any 
dominant negative effects. 
 Next, to cast light on mechanisms mediating Foxg1-dependent repression of these genes, we selected a 
set of putative Foxg1-binding sites (BSs) within Gfap, S100b and Aqp4 promoters (2 for Gfap, 3 for S100b and 2 
for Aqp4), by Jaspar software (Mathelier et al. 2014) (Fig. S2E-G). Then, we monitored the actual recruitment of 
Foxg1 to these sites, both in control and Foxg1-GOF cells, by ChIP-qPCR. To this aim, we employed chromatin 
extracted from derivatives of E12.5 cortico-cerebral precursors, processed as in Fig. 3C. We found that the 
chromatine enrichment elicited by aFoxg1 ranged from 0.63±0.17% (Aqp4_Foxg1-BS.a, n=4,4) to 3.36±1.87% 
(S100b_Foxg1-BS.a, n=4,4) in control samples, well above the background ChIP signal given by control IgG. 
Moreover, such enrichment did not generally change in Foxg1-GOF samples, suggesting that Foxg1 binds to 
these sites with high affinity. In the only case of Gfap_Foxg1-BS.b, this enrichment – about 1.36±0.32% in 
controls – arose up to 2.29±0.12% upon Foxg1 overexpression (p<1.7*10-3, n=4,4) (Fig. 3D). This means that 
this interaction could contribute to differential regulation of Gfap in Foxg1-GOF samples.	
 
Foxg1 antagonizes astrogenesis via a pleiotropic impact on key pathways tuning astroglial genes. 
 In addition to its direct effect on astroglial genes, we hypothesized that Foxg1 might further dampen 
their activity indirectly, by impacting trans-active modulators of their transcription. In particular, we focused our 
attention on four key pathways involved in fundamental control of astroglial gene transcription: 
IL6/Jak2/Stat1,3; Bmp/Smad1,5,8; Nrg1/ErbB4ICD-NCoR; Dll1/Notch1ICD. For these pathways, we measured 
nuclear levels of their ultimate nuclear effectors (modulating gene transcription) within Foxg1-GOF, Nestin+ 
NSCs. We also evaluated nuclear NSC levels of a key antagonist of the IL6/Jak2/Stat1,3 pathway, Neurog1. We 
acutely engineered E12.5 corticocerebral precursors, making them to overexpress Foxg1 in the neurostem 
compartment. We kept these precursors in culture under growth factors for seven days, and we finally co-
immunoprofiled them for Nestin and the six effectors in order, each evaluated by quantitative 
immunofluorescence (qIF): p[Tyr705]Stat3,   p[Ser463/465]Smad1,5,8, Neurog1, ErbB4ICD, NCoR1, and Notch1ICD 
(Fig. 3E). We found that p[Tyr705]Stat3,   p[Ser463/465]Smad1,5,8, and Notch1ICD were downregulated, by -
58.28±1.99% (p<2.5x10-10, n=300,310), -52.91±2.34% (p<5.8x10-23, n=270,220), and -13.78±1.20% (p<2.7x10-
7, n=207,404), respectively. ErbB4ICD was unaffected. Conversely, Neurog1 and NCoR1 were slightly, albeit 
significantly upregulated, by +8.75±3.56% (p<0.032, n=182,150) and +14.18±2.83% (p<0.0002, n=212,281), 
respectively (Fig. 3G and S4C-H). 
 To address the relevance of such changes to astrogenesis inhibition, we functionally counteracted them 
by transducing E12.5 neocortical precursors, made acutely Foxg1-GOF, with pre-validated (Fig. S3D-G), 
“rescuing” Xi lentiviruses.  We kept engineered cells as proliferating neurospheres for seven days under growth 
factors. We allowed them to differentiate for four more days. Finally, we evaluated their S100b+ astroglial output 
(Fig. 3F). We found that constitutively active Stat3 (caStat3) (Hillion et al. 2008) lessened the astroglial deficit 
elicited by Foxg1 overexpression, however only to a limited extent (normalized against controls, this deficit 
moved from -66.46±3.15% to -49.70±6.29%, p<0.03, n=4,4). Conversely, constitutively active Smad1 
(Fuentealba et al. 2007) (caSmad1), alone or in combination with caStat3, fully restored the normal astroglial 
output. In a similar way, functional NCoR1 inhibition, via knock down of its necessary Tab2 cofactor (Sardi et 
al. 2006), considerably reduced the Foxg1-dependent astrogenic deficit (Fig. 3H and S6A-D). Remarkably, in all 
these cases the delivery of the “rescuing agent” to control cultures did not upregulate astrogenesis rates [caStat3 
and caSmad1 reduced the output of these cultures (Fig. 3H), possibly because of premature shrinkage of their 
neurostem compartment (Fig. S5A)]. All this suggests that each of these agents did not simply mask the 
astrogenic deficit elicited by Foxg1 overexpression, via compensatory mechanisms independent from Foxg1 
regulation. It rather indicates that they abolished molecular abnormalities which specifically mediate the impact 
of Foxg1 overexpression on astrogenesis. Last, NSC transduction of a constitutively active NotchICD transgene 
(Cassady et al. 2014) failed to rescue the hypo-astrogenic Foxg1-GOF phenotype. Moreover, it reduced the 
Gfap+ astroglial output of both control and Foxg1-GOF cultures, from 100±8.35% to 21.64±2.48% (control-
normalized frequencies, p<0.001, n=4,4), and from 40.28±5.63% to 26.34±4.71% (control-normalized 
frequencies, p<0.001, n=4,4), respectively (Fig. 3H and S6E). This phenomenon was unexpected. It likely 
reflected the defective capability of derivatives of NotchICD-overepressing NSCs to respond to astrogenic 
cytokines and activate the mature astroglial marker Gfap (Fig. S5B).	
 Next, we investigated basic mechanisms leading to pStat3 and pSmad1,5,8 deficits. We evaluated the 
impact of Foxg1 manipulations on key players implicated in the corresponding signalling machineries (Fig. 4A). 
As for the IL6/Jak2/Stat1,3 axis, we found a significant downregulation of Gp130-, Jak2- and Stat3-mRNAs 
(Gp130: -24.51±6.53%, p<0.05, n=6,6; Jak2: -54.33±6.52%, p<0.0002, n=6,6; Stat3: -32.26±8.88%, p<0.03, 
n=6,6) and no changes for Il6Ra-mRNA in Foxg1-GOF cultures (Fig. 4B). Jak2- and Stat3-mRNA were 
conversely upregulated in Foxg1-LOF cultures (Jak2: +13.32±3.80%, p<0.02, n=6.6; Stat3: +10.59±2.44%, 
p<0.02, n=6.6), whereas Gp130- and Il6Ra-RNA were unaffected (Fig. 4C). Concerning the Bmp/Smad1,5,8 
pathway, BmpRII-mRNA was downregulated in Foxg1-GOF samples (-29.59±11.44%, p<0.03, n=6.6) (Fig. 4B) 
and unaffected in Foxg1-LOF ones (Fig. 4C). Bmp4 was not affected at all. Last, NCoR1-mRNA levels, 
implicated in the balance between NotchICD and ErbB4ICD-mediated signalling, did not show any significant 
change either in Foxg1-GOF and -LOF cultures (Fig. 4B,C). Finally, as a proof-of-principle, to assess relevance 
of the changes described above to the Foxg1-GOF astroglial phenotype, we counteracted the Jak2-mRNA 
decline peculiar to Foxg1-GOF neocortical precursors by a lentiviral expressor encoding for the constitutively 
active, JAK2V617F mutant kinase (Vainchenker 2005), and we evaluated the impact of this manipulation on Gfap+ 
cell frequency (Fig. 4D). Interestingy, the introduction of a JAK2V617F transgene in Foxg1-GOF cultures 
mitigated the decline of Gfap+ cells caused by Foxg1 overexpression, which moved from -43.13±4.02% to -
30.26±2.84% (control-normalized frequencies, p<0.020, n=4,4). The frequency of these cells was conversely 
unaffected, when JAK2V617F was delivered to controls (Fig. 4E and S6F). All this suggests that the 
downregulation of Jak2 (and, possibly, other Foxg1-sensitive, IL6/Jak2/Stat1,3- and Bmp/Smad1,5,8- signaling 
mediators reported above) may contribute to Foxg1 inhibition of astroglial genes expression.	
 
Foxg1 impairs transactivating abilities of the pStat3-pSmad1,5,8 complex. 
 It was previously shown that Foxg1 chelates Smad1 and Smad4 (Rodriguez et al. 2001). Therefore, we 
wondered if it may antagonize astrogenesis, by impairing intrinsic transactivating abilities of these Bmp 
signalling effectors. To address this issue, we acutely engineered E12.5 neocortical precursors with two 
transgenes, encoding for constitutively active Stat3 (caStat3) and Smad1 (caSmad1), driven by a constitutive 
promoter (Pgk1-p). To sense the activity of the resulting caStat3-caSmad1 complex in a way independent of 
possible local epigenetic effects of Foxg1 on astroglial gene chromatin, we employed a synthetic Bmp-signalling 
sensor (BmpRE-ZsGreen), delivered via a randomly integrating lentivector. To so-engineered neural cells, we 
concomitantly delivered a Foxg1-expressing lentivirus or a control. We kept these cells for ten days in pro-
proliferative conditions and, lastly, we profiled them for EGFP fluorescence by cytofluorimetry (Fig. 4F). We 
found that both the frequency of ZsGreen+ cells and the median fluorescence intensity of ZsGreen+ cells were 
reduced in Foxg1-GOF samples, by 38.38±6.63% (control-normalized value, p<0.05, n=4,4), and 26.88±2.78% 
(control-normalized value, p<0.001, n=4,4), respectively (Fig. 4G). Conversely, in a parallel control assay where 
the BmpRE-ZsGreen Bmp-signalling sensor was replaced by a pPgk1-mCherry transgene, no mCherry 
expression decline was detectable in Foxg1-GOF samples (not	shown). These results suggest that Foxg1 may 
dampen the intrinsic, pSmad1/4 transactivating power.	
 
Foxg1 NSC expression levels progressively decline before the perinatal astrogenic burst. 
 We wondered if Foxg1 anti-astrogenic activity might be instrumental in the proper temporal progression 
of astrogenesis. Specifically, we hypothesized that high Foxg1 levels in early NSCs could refrain them from 
differentiating to astroblasts, while lower levels peculiar to later NSCs could be permissive to such 
differentiation. To address this issue, we measured Foxg1-mRNA and -protein levels within pallial stem cells of 
different ages. 
 In a first assay, we employed derivatives of E11.5 pallial precursors, cultured in pro-proliferative 
medium for 2 up to 7 days. From these cultures we FACsorted samples of NSCs (identified as pNes-
EGFP+pTa1-mCherry-, upon lentiviral transduction of these reporters) at DIV2 and DIV7, approximately 
corresponding to in vivo E13.5 and E18.5, respectively. We analyzed their RNA and we found a significant 
decrease of Foxg1-mRNA level in DIV7 compared to DIV2 samples (-59.47±5.11%, p<0.01, n=5,5). Here, as 
controls, we also measured expression of Zbtb20 and Neurog1, two genes active in NSCs according to opposite 
temporal progressions (Hirabayashi et al. 2009; Ohtsuka et al. 2011). As expected, Zbtb20 and Neurog1 were 
increased and decreased, respectively, in more aged samples (Fig. 5A,B). In a second assay, we evaluated Foxg1 
protein level in DIV2 and DIV6 Nestin+ NSC derivatives of E12.5 acutely dissociated neocortices, by double 
aNestin-aFoxg1 qIF. Compared to DIV2 samples, Foxg1 level was diminished by 52.55±1.47% at DIV6 
(p<3.6*10-10, n=288,229) (Fig. 5C,D), confirming that a robust Foxg1 expression decline occurs in neocortical 
stem cells concomitantly with the neuronogenic-to-astrogenic transition.	
 To corroborate these findings, we compared in vivo Foxg1 expression at late vs early neuronogenic 
stages of neocortical development. As expected, we found that periventricular Foxg1 levels overtly declined at 
E16.5 with respect to E12.5 (Fig. 5F). Consistently, qIF profiling of acutely dissociated neocortices  showed that 
a -27.19±1.2% Foxg1 decline  (p<8.18*10-40, n=407,278) specifically occurred in E16.5 Nestin+ NSCs compared 
to E12.5 ones (Fig. 5G,H). In other words the Foxg1 decline preceded the transition from neuronogenesis to 
astrogenesis, suggesting it could be instrumental in arousal of the latter.	
 
Foxg1 antiastrogenic activity is conserved in human pallial precursors. 
 To assess if FOXG1 antagonizes astrogenesis progression in humans like in rodents, we run an ad hoc 
GOF assay in late pallial precursors derived from a legal, human PCW10 abortion, pre-expanded in vitro over 
about 150 days. At the beginning of the procedure (DIV 0), we transduced these precursors with two 
lentiviruses, expressing the rtTAM2 transactivator under the constitutive Pgk1 promoter and Foxg1 (or a control) 
under the rtTAM2/doxycycline-responsive TREt promoter (Fig. 6A). We kept the engineered cells for 7 days in 
proliferation medium and 7 more days in differentiation medium. We exposed them to 9ng/ml doxycyclin from 
DIV0 to DIV11 (so eliciting a final expression gain about 4, not shown) and we immunoprofiled their 
derivatives at DIV15 for S100b (which is mainly confined to cells expressing the pan-astrocytic marker AldoC 
in these cultures; not shown). It turned out that S100b+ astrocyte frequency was reduced by -51.29±8.05% in 
Foxg1-GOF samples compared to controls (p<0.006, n=4,4) (Fig. 6A and S7A). To get a closer insight into 
FOXG1 role in human NSC fate choice, we run an additional GOF assay, differing from the previous one in 
three aspects. We restricted Foxg1 overexpression to the NSC compartment, under the control of the pNes 
promoter; we shortened the differentiation phase of the procedure by 4 days; we exposed the engineered cells to 
a terminal, 24h pulse of LIF. Then, we evaluated the frequency of cells expressing GFAP (specifically detectable 
in astroglial, but also neurostem human cells (Malatesta et al. 2008)) as a proxy of the NSC astrogenic bias (Fig. 
6B). Immunoprofiling of these cultures at DIV10 showed that such frequency was reduced by -27.66±5.41% in 
Foxg1-GOF samples compared to controls (p<0.003, n=4,4) (Fig. 6B and S7B). All this supports the hypothesis 
that Foxg1 may antagonize the NSC astrogenic progression in humans like in rodents.	
 Next, to corroborate these results and rule out that they originated from a dominant negative effect, we 
interrogated a sister preparation of the PCW10 neocortical precursors referred to above, pre-expanded in vitro 
over about 120 days, by a NSC-restricted FOXG1-LOF approach (Fig. 6C and S7C). For this purpose, we 
transduced such precursors by a lentiviral mix encoding for pNes-driven expression of miR.aFoxg1.1690 (this is 
an RNAi effector decreasing FOXG1-mRNA levels by about 42% upon constitutive, Pgk1p-driven expression in 
mixed neural cultures; data not shown). Then, we kept transduced cells 7 days in proliferative medium and 3 
more days in a differentiative medium, terminally supplemented by Lif. Finally, we immunoprofiled cells for 
neurostem/astroglial markers. Frequency of Egfp-GFAP+ astrocytes was unaffected. Conversely, normalized 
against controls, Egfp+GFAP± NSCs were reduced by -26.97±7.82% (p<0.025, n=3,3). All this points to a robust 
increase of  the NSC-normalized GFAP+ astroglial output (normalized against controls, +58.59±3.83%, p<0.003, 
n=3,3) (Fig. 6C). It further suggests that the negative FOXG1 impact on NSC astrogenic progression emerging 
from overepression assays is a genuine GOF phenotype. 
 Last, to assess a possible conservation of mechanisms mediating Foxg1 impact on astrogenesis 
progression, we downregulated FOXG1 in human, PCW10+DIV120 neocortical precursors by a constitutively 
expressed RNAi effector (aFoxg1-shRNA) and monitored the impact of this manipulation on human orthologs 
of murine mediators of this activity (Fig. 6D). We found that, upon a -22.19±3.73% decline of FOXG1-mRNA 
(p<0.049, n=3,3), ZBTB20-mRNA was upregulated  by +26.48±2.72% (p<0.005, n=3,3), and COUPTF1, SOX9 
and NFIA were unaffected. Moreover, mRNAs of Egfp and ZsGreen reporters, driven by pStat1,3- and Bmp-
responsive elements (REs) and co-delivered to neural cells by dedicated lentivectors with a Pgk1p-driven 
mCherry normalizer, were also robustly upregulated, by +252.55±105.72% (p<0.025, n=3,2) and 
+168.81±71.90%  (p<0.050, n=3,3), respectively (Fig. 6D). All that suggest that key molecular mechanisms 
mediating Foxg1 control of astrogenesis are shared by placental mammals. 
 
DISCUSSION 
 In this study we showed that Foxg1 overexpression within murine neocortical stem cells antagonizes the 
generation of astrocytes, in vivo as well as in vitro, while stimulating NSC self-renewal and promoting 
neuronogenesis (Fig. 1). We discovered that Foxg1 antiastrogenic activity can originate from four concurrent 
mechanisms. Foxg1 trans-represses key transcription factor genes promoting the NSC-to-astrocyte progenitor 
progression (Fig. 2). It also directly trans-represses astroglial genes, i.e. genes implementing the astroglial 
differentiation program (Fig. 3A-D). Next, it tunes multiple key pathways controlling astroglial gene 
transcription, unbalancing nuclear concentration of their ultimate effectors (pStat3, pSmad1,5,8, NCoR1, 
NotchICD) and so further dampening astroglial gene expression (Fig. 3E-H and 4A-E). Last, it jeopardizes trans-
activating abilities of one of these effectors, the pStat3-pSmad1,5,8 complex (Fig. 4F,G). Moreover, we found 
that Foxg1 levels within neocortical NSCs progressively decline prior to the neuronogenic-to-gliogenic 
transition (Fig. 5), suggesting an involvement of Foxg1 in fine temporal tuning of astrogenesis rates. Finally, we 
provided a proof-of-principle that a similar anti-astrogenic activity is played by Foxg1 in human neocortical 
precursors (Fig. 6), pointing to such activity as an evolutionarily conserved trait. 
 Interestingly, a robust Foxg1-dependent inhibition of astrogenesis was observed in vivo, upon a variety 
of functional assays (Fig. 1A-G). In particular, a shrinkage of the astroglial output occurred only when Foxg1 
was upregulated (Fig. 1E,G and 6A-C), ruling out any artifactual dominant negative effect. Furthermore, after 
normalization of such output against the starting size of the NSC compartment (Fig. 1E,F and 6A-C), Foxg1 
capability to inhibit astrogenesis emerged upon both gain- and loss-of-function approaches, suggesting that this 
process is sensitive to even subtle changes of Foxg1 levels around baseline. Noticeably, these observations were 
performed upon transplantation of neural precursors pre-manipulated in vitro by lentiviral transgenesis, an 
approach allowing for stable and accurate control of gene expression levels. 
 Next, the astrogenesis decline evoked by Foxg1 overexpression in NSCs was not simply due to a general 
differentiation deficit of neocortical precursors. In fact, it was associated to a pronounced, absolute increase of 
neuronogenesis (Fig. 1H,I). As emerging from clonal assays (Fig. 1N-P), this did reflect a net, consistent shift in 
the NSC histogenetic choice. This means that channelling NSCs towards neuronal rather than glial fates is a 
genuine, key role exerted by Foxg1 in normal development. 
 Last, an anti-astrogenic activity was observed when NSC-restricted Foxg1 overexpression was switched 
on in vivo, in a late-neuronogenic, isochronic environment (Fig. 1C,G). Moreover, clone founder cells showed 
an altered astrogenic bias following Foxg1 manipulation during the neuronogenic phase (Fig. 1N-P). Not least, 
Foxg1 NSC levels (both mRNA and protein) turned out to progressively decline, while moving from early 
neuronogenic stages to subsequent gliogenic phases (Fig. 5).  All this suggests that a progressive decline of 
Foxg1 levels is among key factors dictating age-dependent, NSC developmental choices (Ohtsuka et al. 2011; 
Okamoto et al. 2016).	
 As for cellular articulation of Foxg1 activity, it has to be emphasized that astrogenesis inhibition was 
detectable upon NSC-restricted Foxg1 overexpression (Fig. 1A,C,D,H,N and 6B), by scoring progenies of 
engineered neural precursors transplanted in wild type brains (Fig. 1E,G) or allowed to differentiate in vitro 
(Fig. 1I,O and 6B). It is known that, despite the relevance of environmental signals to the progression of early 
pallial precursors towards gliogenesis (Morrow et al. 2001), such progression can largely occur in a clone-
autonomous way (Qian et al. 2000). Our data indicate that Foxg1 largely acts via cell-autonomous mechanisms 
and contributes to intra-clonal astrogenesis control (Fig. 1Q,R).	
 Concerning molecular articulation of Foxg1 activity, this was quite complex. Foxg1 targets included 
genes involved in both choice and implementation of the astrogenic program. Moreover its impact on these 
targets was direct as well as indirect (Fig. 7). 
 First of all, Foxg1 down-regulated selected transcription factor genes which normally promote NSC 
acquisition of astrogenic competence (Fig. 2A-F). These were: Zbtb20 and its Couptf1 target, stimulating the 
histogenetic progression of neocortical precursors and specifically increasing their responsivity to astrogenic 
cytokines (Naka et al. 2008; Nagao et al. 2016; Tonchev et al. 2016), as well as Sox9 and its Nfia target, both 
promoting the respiration increase associated to the NSC-to-astrocyte progenitor transition (Kang et al. 2012), 
the latter sustaining astroglial gene promoter demethylation (Namihira et al. 2009). Apparently, all four genes 
were directly trans-repressed by Foxg1 (Fig. 2J,K). However, indirect mechanisms also likely contributed to 
their dynamics. For example, the drop of Sox9-mRNA might have been exacerbated by the Foxg1-dependent 
collapse of the IL6/Jak2/Stat3 pathway, which normally sustains its expression (Hall et al. 2017; Jeselsohn et al. 
2017). In a similar way, the decrease of Nfia-mRNA might reflect the downregulation of both Sox9, acting 
upstream of it (Kang et al. 2012), and nuclear NotchICD, also promoting its transcription (Namihira et al. 2009). 
Conversely, Zbtb20, insensitive to caStat3, Bmp4, NotchICD, Sox9 or Nfia (Nagao et al. 2016), might have been 
suppressed by Foxg1 via prevalently direct mechanisms. Intriguingly, Zbtb20 and Foxg1 play contrasting roles 
in other key neuro-developmental scenarios too, e.g. in medial-lateral pallial specification, as promoters of 
archicortical and neocortical fates, respectively (Muzio and Mallamaci 2005; Nielsen et al. 2007, 2010).	
 Next, Foxg1 further repressed genes which implement the astroglial program within committed 
progenitors and their mature progenies, such as Gfap, S100b, Aqp4 (Fig. 3A,B). Even in this cases, gene down-
regulation was likely mediated by direct (Fig. 3C,D) as well as indirect (Fig. 3E-H) mechanisms. 
 Among the most prominent molecular changes underlying Gfap downregulation, there was the 
pronounced pSmad1,5,8 decrease evoked by Foxg1 overexpression in NSCs (Fig. 3F,G), possibly as a 
consequence of reduced sensitivity of these cells to Bmp ligands (Fig. 4A,B). Moreover Foxg1 apparently 
jeopardized the transactivating abilities of the “active Smad1-active Stat3”-containing complex (Fig. 4F,G), 
likely by chelating Smad1, as already described in heterologous systems (Rodriguez et al. 2001). However, the 
Smad1,5,8 machinery is limiting to both neuronogenesis and astrogenesis progression (Nakashima 1999; Sun et 
al. 2001; Hirabayashi et al. 2009). Therefore, a Bmp signalling decrease should be able to simply exacerbate the 
absolute astrogenic deficit evoked by Foxg1, not cause it. We propose that this deficit primarily stem from the 
collapse of pStat3 (Fig. 3F,G), in the presence of sustained Neurog1 expression (Fig. 3G). The former was 
reasonably due to the down-regulation of at least three key components of the corresponding signalling cascade 
(Fig. 4A,B). The latter, at odds with Foxg1-dependent upregulation of the canonical Neurog1 inhibitor, Hes1 
(Chiola et al. in press; Cau et al. 2000; Brancaccio et al. 2010), was perhaps promoted by Foxg1 via Pax6 
(Blader 2004; Manuel et al. 2010). Regardless of mechanisms unbalancing their levels, both pStat1 and Neurog1 
are known to compete for limited p300 and pSmad1 cofactors available, to form an active trimer which 
transactivates astroglial or neuronal genes, respectively (Nakashima 1999; Sun et al. 2001). In this way, in the 
presence of reduced pSmad1 levels, even a moderate decline of the pStat1/Neurog1 ratio may have a truly 
disruptive effect on astroglial genes activation.	
 In a similar way, even the subtle changes of nuclear NCoR1 and NotchICD evoked by Foxg1 (Fig. 3G) 
might significantly concur to defective astrogenic performances of Foxg1-GOF NSCs. In fact, both these factors 
compete for the same RBPJk bridge (Kao et al. 1998), mediating their interaction with astroglial genes (Ge et al. 
2002; Hermanson et al. 2002). In this way, the increase of the NCoR1/NotchICD ratio occurring in Foxg1-GOF 
NSC nuclei ((114.18/86.22-1)*100% = +32.42%, see Fig. 3G) might severely unbalance this competition, so 
resulting in prevailing inhibitory, RBPJk-mediated inputs to astroglial promoters. To note, the moderate 
upregulation of nuclear NCoR1 occurring in Foxg1-GOF samples (Fig. 3G), not due to NCoR1 gene 
transactivation (Fig. 4A,B), could reflect the decline of the IL6/Jak2/Stat3 cascade, instrumental in its nucleus-
to-cytoplasm translocation (Sardi et al. 2006). As for NotchICD, we largely ignore mechanisms underlying its 
dynamics. Moreover, the apparently negative impact of its overexpression on the astroglial output  (Fig. 3G and 
S5B) deserves further investigations.	
 Last, Foxg1 regulation of astrogenesis is not peculiar to rodents. In fact, we found that similar 
phenomena can be detected when Foxg1 expression levels are manipulated in human pallial precursors. In this 
respect, it has been shown that an abnormal FOXG1 copy number results in severe neurological pathologies, 
such as a variant of Rett syndrome, linked to FOXG1 haploinsufficiency (Guerrini and Parrini 2012), and a 
variant of West syndrome, associated to FOXG1 duplication (Pontrelli et al. 2014). It is tempting to speculate 
that an alteration of astrogenesis profiles may take place in these patients and concur to their neurological 
symptoms.	
 In synthesis, we have found that Foxg1 antagonizes astrogenesis in the developing rodent neocortex. We 
have disentangled a large body of molecular mechanisms mediating this activity. We have shown that Foxg1 
may contribute to proper temporal articulation of the NSC histogenetic bias. Finally, we have provided a proof-
of-principle that Foxg1 regulation of astrogenesis can be an evolutionary conserved trait, shared by different 
mammals. 
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LEGEND TO FIGURES 
 
Figure 1. Foxg1 antagonizes astrogenic progression of murine cortico-cerebral stem cells. (A-G) In vivo 
analysis. (A-C) Experimental strategies, (D) lentiviral vectors employed, and (E-G) results. (E, left) (ctr)-
normalized frequencies of Nestin+ derivatives of E12.5 neocortical (ncx) precursors, acutely infected as in (A, 
analysis 1) [absolute frequency of Nestin+ cells in (ctr) samples, 10.38±0.39%]. Analysis performed on cells 
acutely attached on poly-L-lysin-coated coverslips. (E, right) Absolute frequencies of S100β+ astrocytes, 
evaluated within the parietal cortex of P4 pups among derivatives of cells engineered as in (A, analysis 2), and 
co-transplanted as a 1:1 mix into the cortical parietal parenchyma of isochronic P0 pups [average parameter 
value in (ctr) samples, 30.38±2.24%]. (F, left) (ctr)-normalized-frequencies of Nestin+ derivatives of E12.5 
neocortical precursors, acutely infected as in (B, analysis 1) [absolute frequency of Nestin+ cells in (ctr) 
samples,  22.45±1.21%]. Analysis performed on cells acutely attached on poly-L-lysin-coated coverslips. (F, 
right) Absolute frequencies of S100β+ astrocytes, evaluated within the parietal cortex of P4 pups among 
derivatives of cells engineered as in (B, analysis 2), and co-transplanted as a 1:1 mix into the cortical parietal 
parenchyma of heterochronic P0 pups [average parameter value in (ctr) samples, 25.04±2.85%]. (G) Absolute 
frequencies of S100β+ astrocytes, evaluated within the parietal cortex of P4 pups among derivatives of cells 
engineered as in (C), and co-transplanted as a 1:1 mix into the cortical parietal parenchyma of isochronic E14.5 
wild-type embryos [average parameter value in (ctr) samples, 36.27±4.77%]. (H-K) In vitro analysis: neural cell 
frequencies, long protocol. (H,J) Experimental strategy and lentiviral vectors employed for its implementation, 
and (I,K) results. (I) Results of GOF analysis referred to in (H). Analysis 1: ctr-normalized frequencies of 
Sox2+-mCherry- cells at DIV4 [absolute (ctr) frequency, 15.05±0.79%]. Cells acutely attached on poly-L-lysin-
coated coverslips. Analysis 2 results: ctr-normalized frequencies of S100β+, Gfap+ and Tubb3+ cells at DIV11 
[absolute (ctr) frequencies, 14.95±1.27%, 21.67±1.03% and 16.85±3.00%, respectively]. (K) Results of LOF 
analysis referred to in (J). Analysis 1: Ctr-normalized frequencies of Sox2+-mCherry- cells at DIV4 [absolute 
(ctr) frequency, 14.36±0.10%]. Cells acutely attached on poly-L-lysin-coated coverslips. Analysis 2: ctr-
normalized frequencies of S100β+ cells at DIV11 [absolute (ctr) frequency, 25.36±1.70%]. (L,M) In vitro 
analysis: neural cell frequencies, short protocol. (L) Experimental strategy, lentiviral vectors employed, and (M) 
results. Here shown are (ctr)-normalized frequencies of Gfap+ cells among Egfp-expressing derivatives of 
engineered neocortical precursors [absolute (ctr) parameter value,19.06±0.85%]. (N-P) In vitro analysis: clonal 
assays. (N) Experimental strategy, lentiviral vectors employed, and (O,P) results. Here shown are absolute 
frequencies of Tubβ3+Gfap- (neuron-only), Tubβ3-Gfap+ (astrocyte-only), Tubβ3+Gfap+ (neuron-astrocyte-
mixed) clones, as evaluated among total clones originating from E11.5 neocortical precursors, infected and 
processed as in (N). (Q,R) In vitro analysis: cell-autonomous vs non-cell-autonomous mechanisms. (Q) 
Experimental strategy, lentiviral vectors employed, and (R) results. Here, shown are (ctr)-normalized 
Gfap+mCherry+/mCherry+ and Gfap+mCherry-/mCherry- cell number ratios, as well as (ctr)-normalized 
mCherry+ cell frequencies, as evaluated in DIV11 cultures originating from of E12.5 neocortical (ncx) 
precursors, acutely infected and processed as in (Q). [absolute (ctr) parameter values, 56.50±1.70%, 
41.57±1.78%, and 16.12±1.49%,  respectively]. Error bar = s.e.m. n is the number of biological replicates (i.e. 
independently transduced cell samples, or - case  (E, right), (F, right) and (G) - co-transplanted brains). p-value 
calculated by t-test (one-tail, unpaired, or - case (E, right), (F, right) and (G) - one-tail, paired). 
 
Figure 2. Foxg1 downregulates key effectors directing NSCs to astrogenic fates. (A-F) Impact of Foxg1 
manipulation on Couptf1, Zbtb20, Sox9 and Nfia mRNA levels in late embryonic cortico-cerebral precursors. 
(A,B) Experimental protocols, (C) lentiviral vectors employed, and (D-F) results [(D) referring to (A), (E,F) to 
(B)]. Data double-normalized, against endogenous Gapdh-mRNA and (ctr) values. (G-I) Functional relevance of 
Zbtb20 and Nfia misregulation to Foxg1 antiastrogenic activity. This was tested by antagonizing Foxg1-driven 
expression changes of these effectors and interrogating the engineered cultures by clonal analysis, similar to Fig. 
1N,O. (G) Experimental protocol, (C) lentiviral vectors employed, and (H,I) results. (J,K) Chromatin 
ImmunoPrecipitation-PCR (qChIP-PCR) quantification of Foxg1-enrichment at putative Foxg1 binding sites 
within Couptf1, Zbtb20, Sox9 and Nfia loci (named as in Fig. S2A-D): (J) experimental protocol and (K) results. 
Data normalized against input chromatin. Error bar = s.e.m. n is the number of biological replicates (i.e. 
independently transduced cell samples). p-value calculated by t-test (one-tail, unpaired). 
 
Figure 3. Foxg1 represses astroglial-lineage active genes. (A,B) Regulation of astroglial Gfap, S100b and 
Aqp4 genes by Foxg1: (A) experimental strategy, lentiviral vectors employed, and (B) results. Data double-
normalized, against endogenous Gapdh-mRNA and (ctr) values. (C,D) Assaying direct regulation mechanisms: 
Chromatin ImmunoPrecipitation-PCR (qChIP-PCR) quantification of Foxg1-enrichment at putative Foxg1 
binding sites within Gfap, S100b and Aqp4 loci (named as in Fig. S2E-G):  (C) experimental strategy, lentiviral 
vectors employed, and (D) results. Data normalized, against input chromatin. (E-J) Assaying indirect regulation 
mechanisms. (E,G) Modulation of nuclear pStat3, pSmad1,5,8, ErbB4ICD, NCoR1, Notch1ICD protein levels in 
Nestin+, E12.5+DIV7 neural stem cells (NSCs), overexpressing Foxg1, evaluation by quantitative 
immunofluorescence. (E) Experimental protocol, lentiviral vectors employed, and (G) results. Data normalized 
against (ctr). (F,H) Functional relevance of pStat3, pSmad1,5,8, ErbB4ICD, NCoR1 and Notch1ICD 
misregulation to Foxg1 antiastrogenic activity, assessed by counteracting Foxg1-driven changes of these 
effectors and evaluating the resulting S100b+ cell frequency. Constitutively active Stat3 and Smad1 (caStat3 and 
caSmad1) were overexpressed one by one or combined; functional relevance of ErbB4ICD and NCoR1 was 
investigated by dampening their essential Tab2 cofactor. (F) Experimental protocol, lentiviral vectors employed, 
and (H) results. Data normalized against (ctr); absolute frequencies of S100b+ cells: 11.84±2.30% (ctrpStat3), 
8.58±0.43% (ctrpSmad1,5,8), 8.87±0.62% (ctrpStat3-pSmad1,5,8), 21.36±5.27% (ctrTab2); absolute frequencies of 
Gfap+ cells: 37.59±3.14% (ctrNotch1-ICD). Data normalized against (ctr). Error bar = s.e.m. n is the number of 
biological replicates. These are: (B,D,H) independently transduced neural cultures; (G) single cells, randomly 
and evenly picked from 4,4 independently transduced neural cultures. p-values calculated by t-test (one-tail, 
unpaired).	
 
Figure 4. Molecular details of Foxg1 impact on different astrogenic pathways. (A-C) Consequences of 
Foxg1 manipulation on mRNA levels of IL6Ra, Gp130, Jak2, Stat3, Bmp4, BmpRII, NCoR1. (A) Experimental 
protocol and lentiviral vectors employed, (B-C) results. Data double-normalized, against endogenous Gapdh-
mRNA and (ctr) values. (D,E) Functional relevance of Jak2 misregulation to Foxg1 antiastrogenic activity. This 
was assessed by counteracting Foxg1-driven change of Jak2-mRNA and evaluating the resulting S100b+ cell 
frequency: (D) experimental protocol and lentiviral vectors employed, (E) results. Data normalized against (ctr); 
absolute frequency of S100b+ cells in (ctr) samples: 28.70±0.81%. (F,G) Foxg1 impact on trans-activating 
abilities of BMP/Jak-Stat pathways effectors. This was assessed by expressing caStat3 and caSmad1 in E12.5 
neocortical precursor cultures and evaluating their ability to transactivate a lentivector-delivered, randomly 
integrating fluorescent reporter gene, associated to Bmp responsive elements (BMP-RE), upon Foxg1 
overexpression. (F) Experimental protocol, lentiviral vectors employed, and (G) (ctr)-normalized results. 
Analysis by cytofluorometry. Absolute (ctr) frequency of ZsGreen+ cells: 78.50±5.33%. Error bar = s.e.m. n is 
the number of biological replicates. p-values calculated by t-test (one-tail, unpaired). 
 
Figure 5. Neocortical stem cell Foxg1 levels decrease prior to the neocortical astrogenic wave. (A,C) 
Foxg1-mRNA levels in in vitro aging neural stem cells, labelled by lentiviral tracers, identified as pNes-
Egfp+/pTa1-mCherry- and purified by FACsorting. In (A) experimental protocol, in (C) results. Ngn1 and 
Zbtb20 are shown as controls. Data double-normalized, against endogenous Gapdh-mRNA and "E11.5+DIV2" 
values. (B,D,E) Foxg1-protein levels in in vitro aging neural stem cells, recognized as Nestin+ cells and scored 
by quantitative immunofluorescence. In (B) experimental protocol, in (D) results and in (E) example pictures. 
Data normalized against E12.5 average value. Empty arrowheads in (E) point to Nestin+ elements.  (F) In vivo 
distribution of Foxg1 protein in neocortical periventricular layers of E12.5 and E16.5 embryos. (G,H) Foxg1-
protein levels in acutely dissociated, Nestin+ neural stem cells taken from E12.5 and E16.5 neocortices, scored 
by quantitative immunofluorescence. In (G) results, in (H) localization of sampled cells, in (I) primary data 
examples. Empty arrowheads in (I) point to Nestin+ elements. Error bar = s.e.m. n is the number of biological 
replicates. These are: (C) independently transduced neural cultures, or (D,H) single cells, randomly and evenly 
picked from 4,4 independently transduced neural cultures (D) and 4,4 acutely dissociated neocortices (H). p-
values calculated by t-test (one-tail, unpaired). 
 
Figure 6. Foxg1 inhibits progression of human pallial precursors towards astrogenesis. (A-C) Impact of 
FOXG1 modulation on astrogenic outputs of engineered human neocortical precursors: temporal articulation of 
the histogenetic assays, lentiviral vectors employed, and results. The tests were run on late human neocortical 
precursors, derived from PCW10 abortions and pre-expanded in vitro over 150 (A,B) or 120 (C) days. Astrocytic 
outputs were evaluated upon (A) constitutive (pPgk1-rtTAM2-driven) or (B) NSC-restricted (pNestin-rtTAM2-
driven) Foxg1-GOF manipulations, as well as upon (C) constitutive FOXG1 knock-down via a U6 promoter-
driven, aFoxg1-shRNA transgene (FOXG1-LOF samples). Shown are control-normalized frequencies of S100b+ 
(A) and GFAP+ (B,C) cells, and pNesEgfp+GFAP- NSCs (C), as well as control-normalized 
GFAP+/pNesEgfp+GFAP- cell ratios (C). Absolute control frequencies of S100b+ cells (A), GFAP+ cells (B), 
pNesEgfp-GFAP+ cells (C) and pNesEgfp+GFAP± NSCs (C),  24.70±4.00%, 12.62±0.46%, 23.38±1.45% and 
44.16±2.54%, respectively. (D) Modulation of putative genes and pathways mediating the impact of FOXG1 
downregulation on astrogenesis: protocols, lentiviruses employed and results. Shown are control/GADPH-
double-normalized, FOXG1, COUPTF1, ZBTB20, SOX9 and NFIA mRNA levels, as well as control/mCherry-
double-normalized, Egfp (pStat1,3-RE-Egfp) and ZsGreen (BMP-RE-ZsGreen) mRNA levels.  Error bar = 
s.e.m. n is the number of biological replicates, i.e. independently transduced neural cultures. p-values calculated 
by t-test (one-tail, unpaired).  
 
Figure 7. Foxg1 control of astrogenesis: a graphical synopsis. (A) Foxg1 impact on early effectors endowing 
NSCs with astrogenic competence. (B) Foxg1 modulation of genes implementing the astroglial differentiation 
program and their cardinal regulators. 	
 
 
 







